BioSpace News Archive

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare announced that it has filed and is in the process of mailing the management information circular and related materials in connection with the special meeting of its shareholders to be held virtually on March 7, 2023.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on February 6, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 34,163 shares of Puma common stock to four new non-executive employees.

LFA Machines, a subsidiary of Operio Group and a leading global provider of products and support in the tableting and encapsulation industry, announced their new tablet formulation testing services.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today.

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI) today announced the pricing of an underwritten public offering of 4,761,905 shares of its common stock at a public offering price of $21.00 per share, before underwriting discounts and commissions.

Collegium Pharmaceutical, Inc. announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.